文献速递心境障碍物质与行为成瘾儿童青少年精神

青少年大麻使用与成年早期抑郁、焦虑及自杀风险的关联:系统综述与荟萃分析

Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

结果显示大麻使用者成年早期抑郁风险升高(OR 1.37),自杀意念(OR 1.50)和自杀尝试(OR 3.46)风险升高,焦虑风险无统计学意义。

要点

  • 青少年大麻使用与成年早期抑郁风险升高相关(OR 1.37,95%CI 1.16-1.62)。
  • 青少年大麻使用与自杀意念(OR 1.50)及自杀尝试(OR 3.46)风险升高相关。
  • 青少年大麻使用与焦虑的关联无统计学意义(OR 1.18,95%CI 0.84-1.67)。

核心结论

  • 青少年大麻使用与成年早期抑郁、自杀意念和自杀尝试风险升高相关,与焦虑无显著关联。
  • 个体层面风险中低,但青少年大麻使用高流行导致归因于大麻的抑郁和自杀人群数量较大。

研究设计与样本

  • 系统综述与随机效应荟萃分析,检索Medline、Embase、CINAHL、PsycInfo和Proquest至2017年1月。

主要发现

  • 大麻使用者成年早期抑郁的合并OR为1.37(95%CI 1.16-1.62;I2=0%)。
  • 焦虑的合并OR为1.18(95%CI 0.84-1.67;I2=42%),无统计学意义。
  • 自杀意念的合并OR为1.50(95%CI 1.11-2.03;I2=0%)。
  • 自杀尝试的合并OR为3.46(95%CI 1.53-7.84;I2=61.3%)。

关键数值与推荐

  • 纳入研究需评估18岁以下大麻使用并随访至18至32岁抑郁诊断,提取调整基线抑郁和/或焦虑和/或自杀的OR。
  • 抑郁诊断依据DSM第三或第四版或使用预定 cutoff 点的量表。

临床怎么用

  • 在评估青少年精神心理问题时,应将大麻使用作为抑郁和自杀风险的潜在可干预因素纳入考量。
  • 针对青少年大麻使用的公共卫生政策可能有助于降低成年早期抑郁和自杀负担。

局限性

  • 个体层面风险中低,结果需未来足够把握度的前瞻性研究确认。
  • 自杀尝试合并效应异质性较高(I2=61.3%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cannabis is the most commonly used drug of abuse by adolescents in the world. While the impact of adolescent cannabis use on the development of psychosis has been investigated in depth, little is known about the impact of cannabis use on mood and suicidality in young adulthood. OBJECTIVE: To provide a summary estimate of the extent to which cannabis use during adolescence is associated with the risk of developing subsequent major depression, anxiety, and suicidal behavior. DATA SOURCES: Medline, Embase, CINAHL, PsycInfo, and Proquest Dissertations and Theses were searched from inception to January 2017. STUDY SELECTION: Longitudinal and prospective studies, assessing cannabis use in adolescents younger than 18 years (at least 1 assessment point) and then ascertaining development of depression in young adulthood (age 18 to 32 years) were selected, and odds ratios (OR) adjusted for the presence of baseline depression and/or anxiety and/or suicidality were extracted. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Research Triangle Institute item bank on risk of bias and precision of observational studies. Two reviewers conducted all review stages independently. Selected data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: The studies assessing cannabis use and depression at different points from adolescence to young adulthood and reporting the corresponding OR were included. In the studies selected, depression was diagnosed according to the third or fourth editions of Diagnostic and Statistical Manual of Mental Disorders or by using scales with predetermined cutoff points. RESULTS: After screening 3142 articles, 269 articles were selected for full-text review, 35 were selected for further review, and 11 studies comprising 23 317 individuals were included in the quantitative analysis. The OR of developing depression for cannabis users in young adulthood compared with nonusers was 1.37 (95% CI, 1.16-1.62; I2 = 0%). The pooled OR for anxiety was not statistically significant: 1.18 (95% CI, 0.84-1.67; I2 = 42%). The pooled OR for suicidal ideation was 1.50 (95% CI, 1.11-2.03; I2 = 0%), and for suicidal attempt was 3.46 (95% CI, 1.53-7.84, I2 = 61.3%). CONCLUSIONS AND RELEVANCE: Although individual-level risk remains moderate to low and results from this study should be confirmed in future adequately powered prospective studies, the high prevalence of adolescents consuming cannabis generates a large number of young people who could develop depression and suicidality attributable to cannabis. This is an important public health problem and concern, which should be properly addressed by health care policy.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gobbi G, Atkin T, Zytynski T, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019. PMID: 30758486. doi:10.1001/jamapsychiatry.2018.4500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。